Login
Business
Entertainment
World
Health
Environment
Lifestyle
National
Science
Sports
World
Movies
Web Series
Technology
Cricket
Coronavirus
Auto
Ajab Ghazab
Finance
India
International
Religious
Politics
Home Articles Bharat Biotech International Limited BBIL
World’s first intra-nasal vaccine for COVID gets CDSCO nod for restricted use in emergency situations \
3 min read
\
\

World’s first intra-nasal vaccine for COVID gets CDSCO nod for restricted use in emergency situations

 02-Dec-2022
The Central Drugs Standard Control Organization (CDSCO) has approved India's first intra-nasal vaccine for COVID for restricted use in emergency situations in people aged 18 and up.
02-Dec-2022 Health
\
India-made iNCOVACC, world’s first intra-nasal vaccine to receive approval for both primary series, Heterologous booster \
7 min read
\
\

India-made iNCOVACC, world’s first intra-nasal vaccine to receive approval for both primary series, Heterologous booster

 28-Nov-2022
iNCOVACC, on Tuesday, became the world's first intra-nasal vaccine to receive both Primary series and Heterologous booster approval, Bharat Biotech International Limited (BBIL) announced
28-Nov-2022 National
\
DCGI approves ‘5-arms intranasal hetrologous booster dose’ for restricted use \
4 min read
\
\

DCGI approves ‘5-arms intranasal hetrologous booster dose’ for restricted use

 25-Nov-2022
The Drugs Controller General of India (DCGI) has given approval to intranasal "Five Arms" booster dose for restricted use for COVID-19 patients, it is learnt.
25-Nov-2022 National
\
Covaxin safe for children aged 2-18 years, says Bharat Biotech \
3 min read
\
\

Covaxin safe for children aged 2-18 years, says Bharat Biotech

 17-Jun-2022
Hyderabad (Telangana) [India], June 17 (ANI): Bharat Biotech International Limited (BBIL) on Thursday announced that Covaxin, its whole-virion inactivated COVID-19 vaccine has proven to be safe, well-tolerated, and highly immunogenic in paediatric subjects in phase II/III study, said a press release.
17-Jun-2022 National
\